Sobi secures FDA approval for Gamifant to treat MAS in Still’s disease
The FDA approval was based on pooled data from two studies, including a Phase 3 trial, in which 54% of patients achieved a complete response.
KalVista and Pendopharm to collaborate on HAE candidate sebetralstat in Canada
Pfizer’s Hympavzi shows positive results in Phase 3 haemophilia study
Porton Advanced, EVA Pharma partner to expand CAR T-cell therapies
Alvotech-led study finds AVT23 biosimilar matches Xolair’s therapeutic effects
Gilead, Kymera partner to develop novel CDK2 degraders
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery